Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors - Part I

Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors - Part I - new market research report published


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-14 08:59:03 - Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors - Part I - a new market research report on companiesandmarkets.com

New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years.

Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for

 

 

unpartnered products as mature data and approvals come in the next few years.

Report Scope

This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.

1. Drugs in the pipeline
PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)
Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)
BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

2. M&A in Kinase Inhibitors in the last 5 years

3. Related Milestones/catalysts in 2013-14

4. Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.

5. Ongoing Clinical Trials of Companies Covered
Companies Covered -
SymBio pharma (4582, ¥488)
Curis (CRIS, $2.99)
Gilead (GILD, $40.36)
Pharmacyclics (PCYC, $69.28) - Detailed report in Part II of this note
Infinity pharma (INFI, $35.02) - Detailed report in Part II of this note

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com